Cefepime + Ceftolozane + Meropenem + Piperacillin-Tazobactam + Tazobactam
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Other Infectious Diseases
Conditions
Other Infectious Diseases
Trial Timeline
May 16, 2018 → Feb 16, 2022
NCT ID
NCT03485950About Cefepime + Ceftolozane + Meropenem + Piperacillin-Tazobactam + Tazobactam
Cefepime + Ceftolozane + Meropenem + Piperacillin-Tazobactam + Tazobactam is a phase 2 stage product being developed by Merck for Other Infectious Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT03485950. Target conditions include Other Infectious Diseases.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03485950 | Phase 2 | Completed |
Competing Products
20 competing products in Other Infectious Diseases